Powles T, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. ASCO-GU 2019, abstract 543.
Afatinib gevolgd door osimertinib bij EGFR-gemuteerd NSCLC
okt 2018 | Longoncologie